{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:01:21Z","timestamp":1791468081716,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007706","name":"Government of Italy Ministry of Economic Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijbiomac.2026.153093","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:11:33Z","timestamp":1781935893000},"page":"153093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new trastuzumab-ageritin-based immunotoxin that specifically kills breast cancer cells"],"prefix":"10.1016","volume":"378","author":[{"given":"Angela","family":"Oliver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ragucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cantile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Speranza","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannina","family":"Barisciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo V.","family":"Pedone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antimo","family":"Di Maro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Sandomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menotti","family":"Ruvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14737140.2025.2592735","article-title":"Future directions for antibody-drug conjugates in urothelial cancer","volume":"26","author":"D'Agostino","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153093_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13058-025-02151-1","article-title":"Incidence and risk factors for pneumonitis due to trastuzumab deruxtecan in metastatic breast cancer: a retrospective cohort study","volume":"27","author":"Azhar","year":"2025","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0020","first-page":"206","article-title":"Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer","volume":"24","author":"Kubiatowski","year":"2025","journal-title":"Prz Menopauzalny"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153093_bb0025","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.62347\/FOWU3488","article-title":"Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153093_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10677","article-title":"Antibody drug conjugates in the clinic","volume":"9","author":"Udofa","year":"2024","journal-title":"Bioeng. Transl. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.153093_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500305","article-title":"Advanced antibody-drug conjugates design: innovation in linker chemistry and site-specific conjugation technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0045","article-title":"Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates","volume":"164","author":"Chahrour","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1669592","article-title":"Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs","volume":"13","author":"Wu","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153093_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody-drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153093_bb0060","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0065","article-title":"Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153093_bb0075","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/08830185.2025.2545364","article-title":"Antibody-drug conjugates in breast cancer: from therapeutic and immune activation mechanisms to resistance prevention","volume":"44","author":"Nik Amirah Auni","year":"2025","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0080","first-page":"1","article-title":"Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective","author":"Sano","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153093_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213505","article-title":"Trastuzumab-deruxtecan for the treatment of metastatic breast cancer patients: data from real world studies","volume":"17","author":"Quaquarini","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153093_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41568-024-00676-9","article-title":"Trastuzumab: dreams, desperation and hope","volume":"24","author":"Shepard","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0095","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1743517","article-title":"An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?","volume":"12","author":"Moorkens","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122798","article-title":"A single-chain fab derived drug conjugate for HER2 specific delivery","volume":"313","author":"Xu","year":"2025","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153093_bb0105","article-title":"Small-format drug conjugates: a viable alternative to ADCs for solid tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153093_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/08830185.2017.1284211","article-title":"Immunotoxins in cancer therapy: review and update","volume":"36","author":"Akbari","year":"2017","journal-title":"Int. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153093_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12032-024-02478-3","article-title":"Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology","volume":"41","author":"Oghalaie","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1569502","article-title":"Clinically approved immunotoxins targeting hematological cancers: \u201cthe best of both worlds\u201d","volume":"16","author":"Rashad","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153093_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041114","article-title":"A new optimized version of a colorectal cancer-targeted immunotoxin based on a non-immunogenic variant of the ribotoxin alpha-sarcin","volume":"15","author":"Narbona","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/138920108784567254","article-title":"From immunotoxins to immunoRNases","volume":"9","author":"De Lorenzo","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"42","key":"10.1016\/j.ijbiomac.2026.153093_bb0135","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.2174\/1381612820666140826153913","article-title":"Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy","volume":"20","author":"Gilabert-Oriol","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153093_bb0140","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bbagen.2018.09.010","article-title":"Structural and enzymatic properties of Ageritin, a novel metal-dependent ribotoxin-like protein with antitumor activity","volume":"1862","author":"Ruggiero","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"5 Pt A","key":"10.1016\/j.ijbiomac.2026.153093_bb0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.bbagen.2017.02.023","article-title":"Purification, characterization and cytotoxicity assessment of Ageritin: the first ribotoxin from the basidiomycete mushroom Agrocybe aegerita","volume":"1861","author":"Landi","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153093_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13040263","article-title":"Ageritin from pioppino mushroom: the prototype of ribotoxin-like proteins, a novel family of specific ribonucleases in edible mushrooms","volume":"13","author":"Ragucci","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153093_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27082385","article-title":"Ageritin-the ribotoxin-like protein from poplar mushroom (Cyclocybe aegerita) sensitizes primary glioblastoma cells to conventional temozolomide chemotherapy","volume":"27","author":"Rotondo","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153093_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14060403","article-title":"Ribotoxic proteins, known as inhibitors of protein synthesis, from mushrooms and other fungi according to Endo\u2019s fragment detection","volume":"14","author":"Landi","year":"2022","journal-title":"Toxins (Basel)"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153093_bb0165","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.9b00291","article-title":"Ageritin, a ribotoxin from poplar mushroom (Agrocybe aegerita) with defensive and antiproliferative activities","volume":"14","author":"Citores","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153093_bb0170","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jb\/mvab062","article-title":"Toxicity and membrane perturbation properties of the ribotoxin-like protein ageritin","volume":"170","author":"Lampitella","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijbiomac.2019.06.125","article-title":"Binding and enzymatic properties of ageritin, a fungal ribotoxin with novel zinc-dependent function","volume":"136","author":"Ruggiero","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153093_bb0180","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jb\/mvy113","article-title":"Structural insights into nucleotide and protein sequence of ageritin: a novel prototype of fungal ribotoxin","volume":"165","author":"Landi","year":"2019","journal-title":"J. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0185","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijbiomac.2022.09.103","article-title":"Conformational stability of ageritin, a metal binding ribotoxin-like protein of fungal origin","volume":"221","author":"Lampitella","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0190","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1016\/j.ijbiomac.2020.09.050","article-title":"Generation and testing of engineered multimeric Fabs of trastuzumab","volume":"164","author":"Selis","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153093_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17040491","article-title":"Pegylated trastuzumab fragments acquire an increased in vivo stability but show a largely reduced affinity for the target antigen","volume":"17","author":"Selis","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbiotec.2019.06.299","article-title":"A comparative analysis of catalytic activity and stability of microbial transglutaminase in controlled denaturing conditions","volume":"302","author":"Caporale","year":"2019","journal-title":"J. Biotechnol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153093_bb0205","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1021\/jf000302k","article-title":"Substrate specificities of microbial transglutaminase for primary amines","volume":"48","author":"Ohtsuka","year":"2000","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/abio.2000.4713","article-title":"A direct continuous spectrophotometric assay for transglutaminase activity","volume":"285","author":"de Macedo","year":"2000","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.peptides.2018.02.006","article-title":"Automatic procedures for the synthesis of difficult peptides using oxyma as activating reagent: a comparative study on the use of bases and on different deprotection and agitation conditions","volume":"102","author":"Caporale","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2016.02.001","article-title":"Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye","volume":"431","author":"Nath","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010208","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: efficacy, toxicity, and resistance mechanisms-a systematic review","volume":"12","author":"Collados-Ros","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.781800","article-title":"Pseudomonas exotoxin-based immunotoxins: over three decades of efforts on targeting cancer cells with the toxin","volume":"11","author":"Havaei","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13036-019-0188-x","article-title":"Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A","volume":"13","author":"Lee","year":"2019","journal-title":"J. Biol. Eng."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153093_bb0240","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5483\/BMBRep.2019.52.8.250","article-title":"A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep."},{"issue":"47","key":"10.1016\/j.ijbiomac.2026.153093_bb0245","first-page":"2845","article-title":"Attempt at prevention and treatment of edemas in orthopedic and traumatologic surgery","volume":"42","author":"Roy-Camille","year":"1966","journal-title":"Sem. Hop."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1385\/MB:18:3:251","article-title":"Chemical construction of immunotoxins","volume":"18","author":"Ghetie","year":"2001","journal-title":"Mol. Biotechnol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153093_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111696","article-title":"Immunotoxins: from design to clinical application","volume":"11","author":"Kreitman","year":"2021","journal-title":"Biomolecules"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.153093_bb0260","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2026.153093_bb0265","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153093_bb0270","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/coa.12602","article-title":"Oesophageal dilatation with the aid of a flexible bronchoscope","volume":"42","author":"Edmiston","year":"2017","journal-title":"Clin. Otolaryngol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13036-024-00418-3","article-title":"Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation","volume":"18","author":"Go","year":"2024","journal-title":"J. Biol. Eng."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153093_bb0280","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1074\/jbc.M115.688010","article-title":"A combination of structural and empirical analyses delineates the key contacts mediating stability and affinity increases in an optimized biotherapeutic single-chain Fv (scFv)","volume":"291","author":"Tu","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.153093_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24142620","article-title":"Cyclization of single-chain Fv antibodies markedly suppressed their characteristic aggregation mediated by inter-chain VH-VL interactions","volume":"24","author":"Yamauchi","year":"2019","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.153093_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176324","article-title":"Evolution of Escherichia coli expression system in producing antibody recombinant fragments","volume":"21","author":"Sandomenico","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153093_bb0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0022-1759(88)90367-5","article-title":"Large scale preparation of immunotoxins constructed with the Fab\u2019 fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain","volume":"112","author":"Ghetie","year":"1988","journal-title":"J. Immunol. Methods"},{"issue":"51","key":"10.1016\/j.ijbiomac.2026.153093_bb0300","doi-asserted-by":"crossref","first-page":"35390","DOI":"10.1074\/jbc.M109.064147","article-title":"Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage","volume":"284","author":"Yan","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153093_bb0305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol. Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:23:57Z","timestamp":1791465837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026030205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"alternative-id":["S0141813026030205"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153093","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new trastuzumab-ageritin-based immunotoxin that specifically kills breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153093"}}